Perioperative Analgesic Modalities for Breast Cancer Surgeries

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04248608

Enrollment

Registered

2020-01-30

Start date

2020-01-28

Completion date

2020-07-01

Last updated

2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia

Brief summary

The incidence of breast cancer is among women world wide, detection increased with introduction of mammography as a screening tool. surgical resection of breast cancer contributes to the generation of acute and chronic post mastectomy pain. This study aims at comparing the effect of erector spinae block versus serratus block versus intravenous morphine in patients undergoing modified radical mastectomy for breast cancer surgeries regarding pain control and possible side effects

Detailed description

One of the most common types of cancer affecting women is breast cancer. Surgical resection is one of the main approaches applied for solid tumors. surgical approach for breast cancer involve the breast region. Various analgesic modalities are used for proper perioperative pain control. Morphine has always been considered as the gold standard analgesic, however opioids have multiple side effects. Several loco-regional techniques have been introduced for breast surgery pain management including serratus plane block (SPB) and erector spinae plane (ESP) block. In this study the investigators are comparing the effect of erector spinae block versus serratus block versus intravenous morphine in patients undergoing modified radical mastectomy for breast cancer surgeries regarding intraoperative and postoperative analgesia, time to first analgesic, any possible side effects

Interventions

PROCEDUREserratus plane block

ultrasound guided block

PROCEDUREerector spinae block

ultrasound guided block

DRUGMorphine Sulfate

intravenous morphine sulfate 0.1 mg/kg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* female 18-65 years old patients undergoing modified radical mastectomy

Exclusion criteria

* patient refusal, local infection at site of block coagulation defect abnormal kidney or liver functions

Design outcomes

Primary

Measure	Time frame	Description
Visual analogue score	24 hours	minimum score (0), maximum score (10) maximum score (10)
Total morphine consumption	24 hours	total morphine in mg received in first 24 hours postoprative
First time to receive morphine	24 hours	first time to receive morphine in the postoperative period (first 24 hours)

Secondary

Measure	Time frame	Description
mean arterial blood pressure	24 hours	hemodynamic parameters
heart rate	24 hours	hemodynamic parameters

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026